{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T05:06:50Z","timestamp":1779772010951,"version":"3.53.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bmc.2025.118326","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T21:49:35Z","timestamp":1753048175000},"page":"118326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery, synthesis and SAR of 3-aryl pyrazolidines, novel dual orexin receptor antagonists for the treatment of sleep disorders"],"prefix":"10.1016","volume":"129","author":[{"given":"Jean-Philippe","family":"Surivet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Vaillant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Gauvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Kiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Kohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118326_bb0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/B978-0-444-59489-1.00003-3","article-title":"Hypocretins and the neurobiology of sleep-wake mechanisms","volume":"198","author":"de Lecea","year":"2012","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.bmc.2025.118326_bb0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrn2092","article-title":"The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness","volume":"8","author":"Sakurai","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bmc.2025.118326_bb0015","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2025.118326_bb0020","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118326_bb0025","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","article-title":"Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders","volume":"16","author":"Muehlan","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.bmc.2025.118326_bb0030","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cmdc.201200025","article-title":"Discovery of [(2R,5R)-5-[(5-fluoropyridin-2-yl)oxy]methyl-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties","volume":"7","author":"Coleman","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2025.118326_bb0035","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1021\/acs.jmedchem.5b00217","article-title":"Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): a potent and efficacious Oral orexin receptor antagonist","volume":"58","author":"Yoshida","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118326_bb0040","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/cmdc.202000453","article-title":"The quest for the best dual orexin receptor antagonist (Daridorexant) for the treatment of insomnia disorders","volume":"15","author":"Boss","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2025.118326_bb0045","doi-asserted-by":"crossref","first-page":"115489","DOI":"10.1016\/j.bmc.2020.115489","article-title":"Discovery of ORN0829, a potent dual orexin 1\/2 receptor antagonist for the treatment of insomnia","volume":"28","author":"Futamura","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118326_bb0050","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s13311-012-0145-6","article-title":"Classification of sleep disorders","volume":"9","author":"Thorpy","year":"2012","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bmc.2025.118326_bb0055","article-title":"Diagnostic and statistical manual of mental disorders","volume":"5","author":"American Psychiatric Association","year":"2013","journal-title":"DSM"},{"key":"10.1016\/j.bmc.2025.118326_bb0060","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bmc.2025.118326_bb0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bmc.2025.118326_bb0070","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bmc.2025.118326_bb0075","author":"Belsomra (suvorexant) US Package Insert"},{"key":"10.1016\/j.bmc.2025.118326_bb0080","unstructured":"Quviviq (daridorexant) Package Insert. United States Food And Drug Administration Full Prescribing Information. Access July 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214985s000lbl.pdf, 2022."},{"key":"10.1016\/j.bmc.2025.118326_bb0085","doi-asserted-by":"crossref","first-page":"118132","DOI":"10.1016\/j.bmc.2025.118132","article-title":"Discovery of IDOR-1117-1680, a dual orexin receptor antagonist with fast onset and short duration of action for the treatment of insomnia","volume":"122","author":"Surivet","year":"2025","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118326_bb0090","doi-asserted-by":"crossref","first-page":"117892","DOI":"10.1016\/j.bmc.2024.117892","article-title":"Discovery, synthesis and SAR of 2-acyl-1-biarylmethyl pyrazolidines, dual orexin receptor antagonists designed as fast and short-acting sleeping drugs","volume":"112","author":"Surivet","year":"2024","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118326_bb0095","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/jpet.117.241596","article-title":"The use of physiology-based pharmacokinetic and pharmacodynamic Modeling in the discovery of the dual orexin receptor antagonist ACT-541468","volume":"362","author":"Treiber","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2025.118326_bb0100","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.xphs.2019.02.005","article-title":"Validation of human MDR1-MDCK and BCRP-MDCK cell lines to improve the prediction of brain penetration","volume":"108","author":"Feng","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmc.2025.118326_bb0105","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1021\/tx0496791","article-title":"Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites","volume":"18","author":"Gan","year":"2005","journal-title":"Chem Res Toxicol"},{"issue":"2","key":"10.1016\/j.bmc.2025.118326_bb0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-1992-34183","article-title":"A diastereoselective synthesis of (dl)-1,3-Diphenyl-1,3-propanediamines","volume":"1","author":"Denmark","year":"1992","journal-title":"Synthesis"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625002676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625002676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:55:29Z","timestamp":1779771329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625002676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":22,"alternative-id":["S0968089625002676"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118326","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery, synthesis and SAR of 3-aryl pyrazolidines, novel dual orexin receptor antagonists for the treatment of sleep disorders","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118326"}}